FLASCO | Association Partnerships

Latest from FLASCO

Roundtable Discussion: Perez Explores Therapeutic Options in RET-Mutated NSCLC

August 08, 2021

Molecular testing practices and treatment decisions can vary for patients with non–small cell lung cancer. Cesar A. Perez, MD, and a group of other physicians discussed next steps in care for a patient with non–small cell lung cancer whose molecular test results revealed a RET mutation.

Treatment Options Differ for Patients With Benign or Malignant Thyroid Cancer

October 29, 2019

Winston Tan, MD, discusses the current treatment landscape for patients with thyroid cancer. He highlighted the importance of first determining if a patient with thyroid cancer has benign or malignant thyroid nodules, which can be identified with the use of diagnostic biopsies. He also discussed the standard-of-care treatment options for these different subtypes of patients once they are identified.

Leading Oncology Education With the FLASCO Rapid Integrations Program

June 26, 2019

The Rapid Integration Program, a training initiative for new physician’s assistants and nurse practitioners working in the field of oncology, is a Florida Society of Community Oncology (FLASCO) initiative that came from an ASCO meeting. Winston Tan, MD, of the Head and Neck Cancer Center at the Mayo Clinic in Jacksonville, Florida, speaking during the 2019 ASCO Annual Meeting, was in attendance at the 2016 ASCO Annual Meeting when the idea for a training program was first introduced.

Addressing the State of Community Oncology in Florida and the Role of FLASCO

June 11, 2019

Eric Harris, DO, hematologist/oncologist, Florida Cancer Specialists, gives Targeted Oncology an insider’s perspective on the current state of community oncology in Florida and some ways the Florida Society of Clinical Oncology (FLASCO) aids in improving patient care by helping physicians.